ForumIAS LATEST
- 31 May |Post Prelims Meet with Ayush Sir | Offline Session to discuss the Post-Prelims agenda | ForumIAS Click Here to register for the event →
- 02 June |Open Session - The PSIR Mark Improvement by Aman Aloon (AIR 295, UPSC CSE 2025)|Click Here to register for the event →
- 04 June | Open Orientation for GSAP 2026| Click Here to register →
- 06 June | Open Orientation on Essay Guidance Program (EGP 2026) Click Here to register →
- 07 June | Open Orientation for Current Affairs for Mains 2026 Click Here to register →
Contents
What is the News?
Drugs Controller General of India(DGCI) has given emergency use authorisation to Corbevax vaccine for use in children between 12 and 18 years of age.
What is Corbevax Vaccine?
Corbevax is India’s first indigenously developed Receptor Binding Domain (RBD) protein subunit vaccine.
Manufactured by: Hyderabad-based Biological E.
Click Here to read more about Corbevax
Is this the first vaccine approved for use in Children?
No, Corbevax is the third vaccine approved by the DCGI for children’s use after Covaxin and Zydus Cadila’s ZyCoV-D.
But currently, only Covaxin is used in the inoculation drive for children in the 15-18 age group.
Source: This post is based on the article “CORBEVAX receives DCGI approval for Emergency Use Authorization (EUA) for 12-18 years age group” published in PIB on 25th February 2022
